BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...
mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As clinical trials advance, Ben Hargreaves finds the technology is poised to ...
On one of the final days of the Biden Administration, the US Department of Health and Human Services (HHS) announced $590 million in support for Moderna to speed the development of mRNA vaccines ...